SlideShare ist ein Scribd-Unternehmen logo
1 von 18
Downloaden Sie, um offline zu lesen
Burke Hedges
Presents
Delivering Solutions Through Evolution
3700 Island Blvd Unit C–208
Aventura, FL 33160
www.stgeorgemed.com
info@stgeorgement.com
St.GeorgeMedicalConfidential
2
The Problem
Our Mission & Approach
The Market
Our Solutions
Our Team
Financials
Our Future
Agenda
1
2
3
4
5
6
7
St.GeorgeMedicalConfidential
3
Abdominal aortic aneurysm (AAA) rupture is the
3rd leading cause of death in men older than 60 in
the United States.
75% of AAA rupture patients bleed out before
reaching the hospital.
90% of AAA rupture patients bleed out before
reaching the operating table.
Current treatments have a 20% failure rate. Failure
can result in AAA rupture.
Many patients don’t qualify for current
treatments, or are told to wait until the risk of
death from rupture exceeds the risk of surgery.
Unmet Needs in the Treatment ofAbdominalAorticAneurysms
Death from AAA Rapture
 Death before reaching OR
 Death before reaching hospital
 Survivors
St.GeorgeMedicalConfidential
4
To create a device that would solve the 20% reoperation rate
associated with conventional stent-graft technology.
To develop additional minimally invasive medical products that
extend quality of life.
To form a team of world-renowned medical device experts and
entrepreneurs.
To lay the groundwork for sales and distribution in Europe, the US,
China, and India.
Launch 15 fully developed IP products through 2017 and become a
leader in the worldwide medical device market.
Our Mission
5
St.GeorgeMedicalConfidential
Our Three Phase Approach
Phase I
Phase II
Phase III
Phase I
Develop Products and Strategic Partnerships
- 3 years (2011 – 2014)
 Develop solutions for the 20% reoperation
rate associated with AAA repair.
 Forge strategic partnerships and alliances.
 Get the CE Mark for products in Europe.
Phase II
Manufacturing and Sales - 2 Years (2014-
2016)
 Manufacture and sell products in Europe,
India, and China.
 Develop additional products.
 Begin clinical trials for the US market.
 Earn $100 million per year in sales with 20%
profits.
Phase III
Exit Strategy (2017)
 Sell intellectual property (IP) and cash out.
 Go public
St.GeorgeMedicalConfidential
6
Market Opportunity – AAA procedures in thousands
 10 million people are
diagnosed with aortic
aneurysm every year,
but in 2012, only
2.9% of patient were
treated.
 This primarily due to
limitations with the
current technology.
 Many patients are
not good candidates
for the procedure.
 Others are asked to
wait until the risk of
rupture exceeds the
risk of surgery.
Addressable Market
St.GeorgeMedicalConfidential
7
Titan AAA
Parodi
Prevents migration without
barbs for solid fixation,
faster healing, and reduced
failure rate.
Doesn’t block access to
important arteries.
Sealing ring prevents leaks
and failures.
Cage-free design doesn’t
interfere with normal
movement.
Adapts to any anatomy, so
more patients will qualify for
the procedure.
Provides stability and prevents
failure due to kinking.
• Patent Protected
Product
• Received European CE
Mark Clearance
Our Solution
Additional Problems in
Interventional Cardiology
St.GeorgeMedicalConfidential
8
Aortic disease is a silent epidemic that
kills approximately 47,000 Americans
every year.
Thoracic aortic aneurysm (TAA) rupture
is the 13th leading cause of death in the
United States.
Mitral Regurgitation (MR) is a life
threatening condition that will affect 5
million people by 2030.
Coronary heart disease is the leading
cause of death worldwide.
The Need for Minimally Invasive
Cardiovascular Treatments
St.GeorgeMedicalConfidential
9
Studies have shown that minimally invasive procedures can:
• Reduce mortality rates by as much as 67%.
• Shorten hospital stays by up to 76%.
• Reduce pain and scarring after surgery.
St. George Medical has developed the first minimally invasive treatments for
thoracic aortic aneurysms and mitral regurgitation.
Our Minimally Invasive Solutions
St.GeorgeMedicalConfidential
10
Thor TAA
Parodi
Prevents blog clots
in the artery, a
problem with
existing technology.
Corstent H Atlas TMV
The first minimally
invasive treatment
for TAA. Patent
approved in the US.
The first minimally
invasive alternative
treatment for Mitral
Regurgitation.
Our Competitive Advantage
St.GeorgeMedicalConfidential
11
Medtronic, Cook, Gore, Endologix, and other current market leaders use
antiquated self-expanding stent technology. St. George Medical is the first to
offer a balloon-expandable stent that offers the following advantages:
Current Technology
Self Expanding
• Lack of adjustability with 13+ sizes.
• Once deployed, the stent is not adjustable.
• Low radial strength makes it prone to migration.
• Uses anchoring barbs that damage the artery wall.
• No sealing ring.
• Fully-caged body with metal stent.
• Not suitable for difficult anatomies with short and
angled necks, so many patients don’t qualify for
the procedure.
• Prone to kinking.
Our Technology
Balloon Expanding
• Adjustable sizing that only requires 2 sizes.
• Adjustable and accurate deployment.
• High radial strength keeps the stent in place.
• Doesn’t require barbs for anchoring.
• Sealing ring to prevent leaks.
• Cage-free body doesn’t limit normal movement.
• Suitable for difficult anatomies because of the
adjustability, secure fixation, sealing ring, and
cage-free body.
• Increased stability prevents kinking.
Regulatory Strategy
St.GeorgeMedicalConfidential
12
Obtain European CE Mark clearance for each product.
• Done for Titan AAA in Q1 2014, Thor in 2015.
Sell and distribute
approved products in
Europe and emerging
markets.
At the same time,
complete US
clinical trials and
prepare for sales
and distribution.
Set up manufacturing
in the United States.
Intellectual Property
St.GeorgeMedicalConfidential
13
Our intellectual property includes 23 international and US
patents with 9 additional pending patent applications.
Our Founder
St.GeorgeMedicalConfidential
14
Dr. George L. de Goicoechea
CEO and Founder of St. George Medical, Inc.
• Inventor and entrepreneur in the cardiovascular device industry.
• Excels at making early-stage businesses profitable.
• Pioneered work on on the pacemaker, vascular grafts for surgical
bypass, and the first minimally invasive aortic aneurysm treatment.
• Previously launched 3 successful startups – Mintec sold to Boston
Scientific for $72 million.
• Father of the $2 billion per year aortic stent graft market.
Medical Advisory Board
St.GeorgeMedicalConfidential
15
Dr. Juan Carlos Parodi – Chairman of the Board
• Co-Inventor of the first endovascular stent graft to treat AAA.
• Revolutionized interventional cardiology.
• Holds key patents related to Titan AAA and Thor TAA.
Dr. Joseph Lamelas – Medical Board
• Chief of Cardiac Surgery at Mt. Sinai Medical Center in Miami.
• Performed more than 7000 open-heart procedures.
• Developing Atlas TMV – the first minimally invasive treatment for MR.
Dr. Eduardo de Marchena– Medical Board
• Professor of Medicine and Surgery at the University of Miami.
• Four-time recipient of the Best Cardiology Attending Award.
• Developing Corstent H - next generation coronary stent technology.
Dr. Claude Mialhe– Medical Board
• Inventor of the Introducer System for large caliber aortic stents.
• Two-time recipient of the Innovation Award in London.
• Developing the Mialhe Introducer System for the Titan AAA.
Management Team
St.GeorgeMedicalConfidential
16
Guro Bjornstad – Vice President of Clinical Development
• 20 years of experience bringing cardiovascular products to market.
• Oversees clinical development for all products at St. George Medical.
Gerald North, Esq. – Antitrust Litigation and Patent Lawsuits
• Experience and success in legal disputes related to AT&T, Gore, and Mintec.
• Oversees patent and legal matters for St. George Medical.
Burke Hedges – Vice President of Corporate Development
• 30 years of business experience with over 20 successful startups.
• Oversees business development for St. George Medical.
Bernhard Neuwirth – Vice President of Sales (Europe)
• Sales experience with prominent companies, including Boston Scientific and J&J.
• Oversees sales for St. George Medical in the European market.
Doug Berkoff – Chief Financial Officer
• 20 years of experience in financial operations management.
• Oversees financial matters for St. George Medical.
Frank Avellanet – Consultant
• 36 years of management experience in the medical device industry.
• Oversees worldwide manufacturing for St. George Medical.
Financials
St.GeorgeMedicalConfidential
17
5-Year Financial Projections
The Future of St. George Medical
St.GeorgeMedicalConfidential
18
St. George Medical recently entered Phase II of its three stage development plan.
The company has initiated the second round of equity funding to support
manufacturing and sales efforts.
With a strong IP portfolio and family of 15 medical device products, St. George Medical
is positioned to become a major player in the medical device industry.
We hope you enjoyed the presentation.
If you’re interested in learning more about St. George Medical, check out:
www.StGeorgeMed.com
If you’re interested in getting involved with the company in its early stages, check out:
www.stgeorgemed.com/investor-contact
A member of our team will get back to your shortly.

Weitere ähnliche Inhalte

Kürzlich hochgeladen

SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)Mohamed Rizk Khodair
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 

Kürzlich hochgeladen (20)

SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 

St. George Medical Investor Presentation

  • 1. Burke Hedges Presents Delivering Solutions Through Evolution 3700 Island Blvd Unit C–208 Aventura, FL 33160 www.stgeorgemed.com info@stgeorgement.com
  • 2. St.GeorgeMedicalConfidential 2 The Problem Our Mission & Approach The Market Our Solutions Our Team Financials Our Future Agenda 1 2 3 4 5 6 7
  • 3. St.GeorgeMedicalConfidential 3 Abdominal aortic aneurysm (AAA) rupture is the 3rd leading cause of death in men older than 60 in the United States. 75% of AAA rupture patients bleed out before reaching the hospital. 90% of AAA rupture patients bleed out before reaching the operating table. Current treatments have a 20% failure rate. Failure can result in AAA rupture. Many patients don’t qualify for current treatments, or are told to wait until the risk of death from rupture exceeds the risk of surgery. Unmet Needs in the Treatment ofAbdominalAorticAneurysms Death from AAA Rapture  Death before reaching OR  Death before reaching hospital  Survivors
  • 4. St.GeorgeMedicalConfidential 4 To create a device that would solve the 20% reoperation rate associated with conventional stent-graft technology. To develop additional minimally invasive medical products that extend quality of life. To form a team of world-renowned medical device experts and entrepreneurs. To lay the groundwork for sales and distribution in Europe, the US, China, and India. Launch 15 fully developed IP products through 2017 and become a leader in the worldwide medical device market. Our Mission
  • 5. 5 St.GeorgeMedicalConfidential Our Three Phase Approach Phase I Phase II Phase III Phase I Develop Products and Strategic Partnerships - 3 years (2011 – 2014)  Develop solutions for the 20% reoperation rate associated with AAA repair.  Forge strategic partnerships and alliances.  Get the CE Mark for products in Europe. Phase II Manufacturing and Sales - 2 Years (2014- 2016)  Manufacture and sell products in Europe, India, and China.  Develop additional products.  Begin clinical trials for the US market.  Earn $100 million per year in sales with 20% profits. Phase III Exit Strategy (2017)  Sell intellectual property (IP) and cash out.  Go public
  • 6. St.GeorgeMedicalConfidential 6 Market Opportunity – AAA procedures in thousands  10 million people are diagnosed with aortic aneurysm every year, but in 2012, only 2.9% of patient were treated.  This primarily due to limitations with the current technology.  Many patients are not good candidates for the procedure.  Others are asked to wait until the risk of rupture exceeds the risk of surgery. Addressable Market
  • 7. St.GeorgeMedicalConfidential 7 Titan AAA Parodi Prevents migration without barbs for solid fixation, faster healing, and reduced failure rate. Doesn’t block access to important arteries. Sealing ring prevents leaks and failures. Cage-free design doesn’t interfere with normal movement. Adapts to any anatomy, so more patients will qualify for the procedure. Provides stability and prevents failure due to kinking. • Patent Protected Product • Received European CE Mark Clearance Our Solution
  • 8. Additional Problems in Interventional Cardiology St.GeorgeMedicalConfidential 8 Aortic disease is a silent epidemic that kills approximately 47,000 Americans every year. Thoracic aortic aneurysm (TAA) rupture is the 13th leading cause of death in the United States. Mitral Regurgitation (MR) is a life threatening condition that will affect 5 million people by 2030. Coronary heart disease is the leading cause of death worldwide.
  • 9. The Need for Minimally Invasive Cardiovascular Treatments St.GeorgeMedicalConfidential 9 Studies have shown that minimally invasive procedures can: • Reduce mortality rates by as much as 67%. • Shorten hospital stays by up to 76%. • Reduce pain and scarring after surgery. St. George Medical has developed the first minimally invasive treatments for thoracic aortic aneurysms and mitral regurgitation.
  • 10. Our Minimally Invasive Solutions St.GeorgeMedicalConfidential 10 Thor TAA Parodi Prevents blog clots in the artery, a problem with existing technology. Corstent H Atlas TMV The first minimally invasive treatment for TAA. Patent approved in the US. The first minimally invasive alternative treatment for Mitral Regurgitation.
  • 11. Our Competitive Advantage St.GeorgeMedicalConfidential 11 Medtronic, Cook, Gore, Endologix, and other current market leaders use antiquated self-expanding stent technology. St. George Medical is the first to offer a balloon-expandable stent that offers the following advantages: Current Technology Self Expanding • Lack of adjustability with 13+ sizes. • Once deployed, the stent is not adjustable. • Low radial strength makes it prone to migration. • Uses anchoring barbs that damage the artery wall. • No sealing ring. • Fully-caged body with metal stent. • Not suitable for difficult anatomies with short and angled necks, so many patients don’t qualify for the procedure. • Prone to kinking. Our Technology Balloon Expanding • Adjustable sizing that only requires 2 sizes. • Adjustable and accurate deployment. • High radial strength keeps the stent in place. • Doesn’t require barbs for anchoring. • Sealing ring to prevent leaks. • Cage-free body doesn’t limit normal movement. • Suitable for difficult anatomies because of the adjustability, secure fixation, sealing ring, and cage-free body. • Increased stability prevents kinking.
  • 12. Regulatory Strategy St.GeorgeMedicalConfidential 12 Obtain European CE Mark clearance for each product. • Done for Titan AAA in Q1 2014, Thor in 2015. Sell and distribute approved products in Europe and emerging markets. At the same time, complete US clinical trials and prepare for sales and distribution. Set up manufacturing in the United States.
  • 13. Intellectual Property St.GeorgeMedicalConfidential 13 Our intellectual property includes 23 international and US patents with 9 additional pending patent applications.
  • 14. Our Founder St.GeorgeMedicalConfidential 14 Dr. George L. de Goicoechea CEO and Founder of St. George Medical, Inc. • Inventor and entrepreneur in the cardiovascular device industry. • Excels at making early-stage businesses profitable. • Pioneered work on on the pacemaker, vascular grafts for surgical bypass, and the first minimally invasive aortic aneurysm treatment. • Previously launched 3 successful startups – Mintec sold to Boston Scientific for $72 million. • Father of the $2 billion per year aortic stent graft market.
  • 15. Medical Advisory Board St.GeorgeMedicalConfidential 15 Dr. Juan Carlos Parodi – Chairman of the Board • Co-Inventor of the first endovascular stent graft to treat AAA. • Revolutionized interventional cardiology. • Holds key patents related to Titan AAA and Thor TAA. Dr. Joseph Lamelas – Medical Board • Chief of Cardiac Surgery at Mt. Sinai Medical Center in Miami. • Performed more than 7000 open-heart procedures. • Developing Atlas TMV – the first minimally invasive treatment for MR. Dr. Eduardo de Marchena– Medical Board • Professor of Medicine and Surgery at the University of Miami. • Four-time recipient of the Best Cardiology Attending Award. • Developing Corstent H - next generation coronary stent technology. Dr. Claude Mialhe– Medical Board • Inventor of the Introducer System for large caliber aortic stents. • Two-time recipient of the Innovation Award in London. • Developing the Mialhe Introducer System for the Titan AAA.
  • 16. Management Team St.GeorgeMedicalConfidential 16 Guro Bjornstad – Vice President of Clinical Development • 20 years of experience bringing cardiovascular products to market. • Oversees clinical development for all products at St. George Medical. Gerald North, Esq. – Antitrust Litigation and Patent Lawsuits • Experience and success in legal disputes related to AT&T, Gore, and Mintec. • Oversees patent and legal matters for St. George Medical. Burke Hedges – Vice President of Corporate Development • 30 years of business experience with over 20 successful startups. • Oversees business development for St. George Medical. Bernhard Neuwirth – Vice President of Sales (Europe) • Sales experience with prominent companies, including Boston Scientific and J&J. • Oversees sales for St. George Medical in the European market. Doug Berkoff – Chief Financial Officer • 20 years of experience in financial operations management. • Oversees financial matters for St. George Medical. Frank Avellanet – Consultant • 36 years of management experience in the medical device industry. • Oversees worldwide manufacturing for St. George Medical.
  • 18. The Future of St. George Medical St.GeorgeMedicalConfidential 18 St. George Medical recently entered Phase II of its three stage development plan. The company has initiated the second round of equity funding to support manufacturing and sales efforts. With a strong IP portfolio and family of 15 medical device products, St. George Medical is positioned to become a major player in the medical device industry. We hope you enjoyed the presentation. If you’re interested in learning more about St. George Medical, check out: www.StGeorgeMed.com If you’re interested in getting involved with the company in its early stages, check out: www.stgeorgemed.com/investor-contact A member of our team will get back to your shortly.

Hinweis der Redaktion

  1. Hello everyone, My name is Melissa Wood and today I’d like to talk to you about a medical device startup called St. George Medical.
  2. Today we’re going to start off by talking about real problems in cardiovascular medicine – because at the end of the day, that’s why St. George Medical was created. They saw a problem and they wanted to solve it. We’ll discuss the company’s approach to solving that problem and provide a brief overview of the solutions. Then we’ll find out who’s behind St. George Medical and discuss the financials before talking about the future of the company.
  3. The problem St. George Medical is trying to solve relates to a condition called abdominal aortic aneurysm, or AAA. It’s essentially a balloon-like formation in the artery that has the potential to pop or rupture. When this happens, it’s not just like getting a cut - it can have fatal consequences. Site the statistics. What are doctors doing about this? Treatments exist, but they don’t always succeed. Site the statistics. Furthermore, many people don’t qualify for the treatment at all – which means that they have to walk around with a ticking time bomb inside their bodies.
  4. The founders of St. George Medical wanted to do something to help patients with AAA. – Point 1 To do it, they formed a team – point 2 Wanted to go further with it – point 3 Get it to doctors so they can help patients – point 4 Goal of the company – point 5
  5. The founder is an experienced inventor and entrepreneur, so he devised a 3 phase plan to get these products into doctor’s hands. Phase I is already complete. Company has just entered phase II. Expects to enter phase III by 2017.
  6. Getting back to the patients – there are 10 million people diagnosed with this condition every year - but only 2.9% are getting treatment. Cite reasons why. That’s why this new device is so important. What is this new device?
  7. It’s called the Titan AAA and it addresses all the issues we just talked about. Each component was specifically designed to fix the issues that cause post-surgical failure and rupture. Briefly cover the points. The inventors were so happy with the outcome, they were fired up to do more. AAA isn’t the only problem in interventional cardiology that needs to be addressed.
  8. Overall aortic disease is a silent killer – cite statistics. There’s another type of aortic aneurysm, called TAA , that occurs in the chest area – cite statistics Mitral regurgitation is a potentially fatal heart condition that’s a growing problem – studies have shown that it will affect 5 million people by 2030. Then you have the big one – coronary heart disease – which is the leading cause of death worldwide, despite the existing treatments. There are treatments that exist for all these conditions, but the team at St. George Medical knew they could do better.
  9. All of the solutions are minimally invasive. That means, instead of having to cut open the entire chest cavity, the patient only needs a tiny incision. This has several benefits – site statistics. None of the conditions we just talked about have minimally invasive treatment options – until now.
  10. St. George Medical has developed 3 additional products that offer significant advantages over current treatments. They are all minimally invasive. Briefly touch on each.
  11. Why are these products so much better than the current treatments? St. George Medical has developed balloon-expanding technology that offers the following benefits – go over comparison. There’s no doubt that St. George Medical is offering superior technology – but how will they get these products to the market?
  12. Simple regulatory strategy – CE Mark -> sales and development -> worldwide markets -> US approval All these products are patent protected…
  13. As you can see, intellectual property is covered. The team has spent a lot of time, money, and resources developing these products, so they wanted to make sure they were fully protected. Let’s talk about the faces behind St. George Medical.
  14. We’ll start by talking about the Founder, Dr. George, as he likes to be called. Hit Dr. G bullet points. Backed by his medical advisory team. Dr. George Full Bio: Dr. George has a prominent history in the medical device industry, both as an innovator and as a successful entrepreneur. He pioneered work on the pacemaker, the Dacron vascular graft for surgical bypass of diseased arteries, and stent grafts for minimally invasive aneurysm repair. A clinical pathologist turned businessman, he excels at making early-stage businesses profitable. He has held a number of executive positions in the industry, has three successful start-ups to his name, and holds 36 patents, many in the cardiovascular field. In 1982, he joined Intermedics, Inc. as President of International Operations and was subsequently named Executive Vice President of the parent company. At the time, Intermedics was operating at a loss. Dr. George consolidated the international sales of all its divisions, increased sales by over 20 percent each year, and turned it around from losses to profits. In 1986, he completed a leveraged buyout of Intervascular, a division that was running at a $2.5 million loss with a single woven graft product. Through his leadership and strategic thinking, he developed new products and expanded sales internationally, rapidly making the company profitable. Shortly thereafter, he formed Mintec to develop the first stent graft for the repair of aortic aneurysms. After reaching $8.5 million in sales and $1.7 million in profit after only 24 months of operation, the company received an offer for $72 million from Boston Scientific. By the time Boston Scientific closed the sale six months later, Dr. George had driven sales to $12 million. As President and Founder of Mintec, Dr. George gave birth to what is now a $2 billion per year industry. Dr. George founded St. George Medical in 2011 and, in a short period of time, he and his team have developed a number of new products for the interventional cardiology field.
  15. Medical advisory board is filled with prominent physicians in interventional cardiology. Go over points for each. Also have to take care of the business side… Parodi Full Bio: Dr. Parodi is the inventor of the endovascular stent graft. He performed the world’s first implant on September 7, 1990. His vision was to find a less invasive way to treat aneurysms in lieu of open surgery. The procedure revolutionized interventional cardiology. Today, endovascular aortic repair is the first-line treatment for abdominal aortic aneurysms. Now, Dr. Parodi is ready to introduce the next generation of minimally invasive cardiology products with the Titan AAA. Lamelas Full Bio: Dr. Lamelas is chief of cardiac surgery at Mount Sinai Medical Center in Miami Beach, Florida. A leading authority in cardiovascular and thoracic surgery, Dr. Lamelas has performed more than 7000 open-heart procedures in his career. His success comes from his ability to provide his patients with every surgical technique and option available in the cardiac surgery field. His new device, called Atlas TMV, will be the first minimally invasive product for mitral valve replacements. Marchena Full Bio: Dr. de Marchena is an internationally recognized cardiologist and professor of medicine and surgery at the University of Miami Miller School of Medicine. Dr. de Marchena has been widely recognized for his clinical accomplishments as a four-time recipient of the Best Cardiology Attending Award presented by the University of Miami Cardiology Fellows (1988-2000). He is currently developing the Corstent, an innovative device that solves common problems associated with conventional coronary stent technology. Mialhe Full Bio: Dr. Claude Mialhe is the co-inventor of the first AAA endoprosthetic device. He is also the inventor of the Introducer system for large caliber aortic stent HQS – for which he was awarded the Innovation Award in London  in 2010 and the multi Xcath access system for complex aortic stent, which allowed him to win the Innovation Award again in 2011. Dr. Mialhe is proud to once again team up with Dr. George to enhance our rich pipeline of innovative products.
  16. Which is why they have an experienced medical team. Go over points. As you can see, St. George Medical has great product and great people – but will this business be profitable? Guro Full Bio: Ms. Bjornstad previously served as Vice President of Endovascular R&D at Vascular Innovation, where she developed a balloon-expandable stent for endovascular aortic repair. Additionally, she led the development and management of several stent graft products and supervised worldwide clinical trials. As part of her role, Ms. Bjornstad provided leadership to a group that guided physicians in over 4,000 endovascular aortic repair implants worldwide. She brings significant experience and expertise to St. George Medical, where she will oversee research and development. Gerald Full Bio: Mr. North has previously served as a board member for several early-stage medical device and healthcare companies. He has extensive experience and success in antitrust litigation and patent lawsuits, including the break-up of AT&T, the 10-year patent/antitrust dispute with Gore, and Mintec’s defense against Datascope. Burke Hedges Full Bio: Burke Hedges is an internationally recognized business thought leader, practitioner, investor, and published author. With over 30 years of business experience, he is known for his ability to launch and manage successful startups in a variety of industries. Mr. Hedges is a highly ambitious entrepreneur with over 20 startups to his name. His work spans 5 continents, where he worked with multi-billion dollar companies in North America, Europe, Asia, Central America, and South America. Doug Berkoff Full Bio: Mr. Berkoff has more than 20 years of experience in financial operations management. He has expertise in a variety of corporate financial affairs, including cost and project accounting, corporate tax, cash flow management, capital budgeting, sales forecasting, and attainment reporting. He has held CFO and senior level management positions in both manufacturing and service-oriented industries, where he managed corporate functions such as sales, production, shipping, receiving, purchasing, information technology, and human resources. Frank Avellanet Full Bio: Mr. Avellanet is an entrepreneur and executive with 36 years of broad management experience in the medical device industry. He has a high level of expertise when it comes to new product design, program management, and clinical testing. Well versed in the process of managing innovation and complex projects, he is a prolific inventor with 27 issued patents and 3 pending patent applications. He currently heads manufacturing worldwide for St. George Medical.
  17. According to the financial projections, the answer is yes. Based on financial projections, the company is set to be profitable in 2015. Add more information about how these figures were calculated when available. To wrap it up…
  18. If you remember, we talked about the three phases of development. St. George Medical has just entered stage two after the approval of the Titan if Q1 2014. Now, they have relocated their headquarters to Clearwater, FL and are in the process of setting up a manufacturing facility. Cover point 2 and 3 Wrap it up.